Systematic ReviewResearchMedication Safety

COPD biologics reduced exacerbations in biomarker-selected patients, with modest lung-function gains

BMJ open respiratory research (PubMed)Jul 14, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A meta-analysis of seven randomized trials found that type 2 inflammation-targeted biologics reduced moderate or severe COPD exacerbations by 23% in biomarker-selected populations, with modest pooled lung-function and quality-of-life gains.

What NurseJet pulled from the source

This systematic review analyzed seven randomized trials of biologics targeting type 2 inflammation in selected patients with COPD. Compared with placebo, biologics reduced the rate of moderate or severe exacerbations (rate ratio 0.77, 95% CI 0.72 to 0.83). Pooled FEV1 improved by 43 mL, and St George's Respiratory Questionnaire scores improved by 2.46 points. The strongest exacerbation reduction appeared with IL-4/IL-13-targeting therapy in patients with blood eosinophils of at least 300 cells per microliter. Serious adverse events did not increase significantly, but patient-selection methods varied across trials.

Why this matters for nurses

Nurses caring for people with COPD assess exacerbation frequency, respiratory status, treatment adherence, injection effects, and barriers to complex regimens. This review supports a biomarker-selected approach rather than assuming biologics benefit all patients with COPD.

Bedside takeaway

COPD biologics reduced exacerbations in selected type 2 inflammation populations, but benefits should not be generalized to unselected patients.

How This Applies in Practice

Use this when: Monitoring a patient receiving a provider-ordered biologic for COPD with type 2 inflammation.

On your shift

Confirm the prescribed agent and schedule and assess interval exacerbations, respiratory symptoms, and adherence barriers.
Monitor for treatment reactions using the approved pathway and report new or worsening respiratory concerns to the care team.

Keep in mind: The evidence applies to biomarker-selected populations and does not determine eligibility for an individual patient. Follow facility policy and patient-specific provider orders.

Explain this for my unit

Key takeaways

Seven randomized trials contributed to the quantitative synthesis.
Type 2-targeted biologics reduced moderate or severe COPD exacerbations by 23% versus placebo.
Pooled lung-function and quality-of-life improvements were modest.
Benefits were most consistent in biomarker-selected populations, particularly for IL-4/IL-13-targeting therapy at higher eosinophil counts.

Practice implications

For a patient receiving an ordered COPD biologic, confirm the medication and schedule, assess interval exacerbations and respiratory symptoms, and monitor for treatment reactions according to the product and facility pathway. Biomarker eligibility and prescribing decisions belong to the respiratory or prescribing team.

Limitations & cautions

Only seven randomized trials were included in the quantitative synthesis. Biologic targets, biomarker thresholds, and patient-selection strategies varied, limiting direct comparisons. The pooled 43 mL FEV1 and 2.46-point quality-of-life changes were modest, and no significant serious-adverse-event increase does not establish identical safety.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

BMJ open respiratory research (PubMed)

BMJ open respiratory research (PubMed). Biologic therapies targeting type 2 inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42448376/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Journal of clinical nursing (PubMed)Jul 17, 2026Systematic ReviewPractice applicable

A systematic review of 11 randomized trials found that nurse-led telehealth reduced HbA1c by a pooled 0.62 percentage points versus usual care, while BMI and fasting plasma glucose did not improve significantly.

Med-SurgAI summaryReview source

Systematic ReviewResearchWorkflowPatient EducationPractice applicableAI summary · original source linked below

This systematic review evaluated nurse-led telehealth for adults with type 2 diabetes. Eleven randomized trials were included and 10 contributed to meta-analysis. Compared with usual care, nurse-led telehealth reduced HbA1c by a pooled 0.62 percentage points (95% CI 0.34 to 0.90 points lower). The pooled BMI difference narrowly crossed no effect, and fasting plasma glucose did not differ significantly. The review supports structured nurse-delivered remote follow-up as an adjunct to routine care, while leaving the best intervention intensity, fidelity, and long-term outcomes uncertain.

Key takeaways

The review included 11 randomized trials, with 10 contributing to meta-analysis.
Nurse-led telehealth reduced HbA1c by a pooled 0.62 percentage points compared with usual care.
BMI showed a borderline nonsignificant difference, and fasting plasma glucose did not differ significantly.
Further trials are needed to define intervention intensity, fidelity, and longer-term outcomes.

Why this matters on shift

Medical-surgical nurses support diabetes education, care transitions, symptom review, and self-management between visits. This review directly evaluates a nurse-led model and suggests that structured remote follow-up can improve an important measure of glycemic control.

Bedside takeaway

Structured nurse-led telehealth improved pooled HbA1c, but the review did not identify one best program design or show clear BMI or fasting-glucose benefit.

Nursing implications

Where an approved telehealth pathway exists, use structured follow-up to review glucose data, self-management barriers, treatment workload, and patient questions. A pooled HbA1c benefit does not establish one best contact schedule or replace individualized goals, medication review, or escalation for concerning symptoms or readings.

Limitations & cautions

Interventions varied in intensity and delivery, one of the 11 trials could not contribute extractable outcome data, and the abstract does not report pooled participant count or longer-term clinical outcomes. The BMI estimate narrowly crossed no effect, and fasting plasma glucose did not differ significantly.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of clinical nursing (PubMed). Effectiveness of Nurse-Led Telehealth Compared With Usual Care on Glycemic Control and Body Mass Index in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Sexually transmitted infections (PubMed)Jul 16, 2026Research ArticlePractice applicable

In a single-center randomized trial of 23 pregnant patients with early syphilis, three weekly benzathine penicillin G doses did not improve maternal serologic response or neonatal outcomes compared with one standard dose.

L&D / OB Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyInfection ControlPractice applicableAI summary · original source linked below

This nonblinded randomized trial enrolled 23 pregnant patients with secondary or early latent syphilis and compared one 2.4-million-unit benzathine penicillin G injection with three weekly injections. Maternal VDRL titers did not differ between groups at delivery or two months postpartum. All neonates were clinically healthy and achieved seroreversion by six months, with no detected group difference in neonatal outcomes. The findings align with current single-dose recommendations for early syphilis in pregnancy, but the very small, single-center sample cannot exclude uncommon or modest differences.

Key takeaways

The randomized, nonblinded trial enrolled 23 pregnant patients with secondary or early latent syphilis.
Maternal VDRL responses did not differ between one-dose and three-dose groups at delivery or two months postpartum.
All neonates were clinically healthy and achieved seroreversion by six months.
The small sample limits confidence about uncommon outcomes and smaller treatment differences.

Why this matters on shift

Obstetric nurses help coordinate timely treatment, allergy verification, injection administration, follow-up testing, partner-service referrals, and newborn evaluation. The trial addresses a common question about whether extra doses improve outcomes in early syphilis during pregnancy.

Bedside takeaway

A small randomized trial found no benefit from three benzathine penicillin doses over one for early syphilis in pregnancy.

Nursing implications

Verify syphilis stage, allergy history, ordered benzathine penicillin product and dose, and the maternal and newborn follow-up plan. Do not add or omit doses based on this small trial; use the applicable obstetric and infection-control protocol and promptly address missed treatment or follow-up.

Limitations & cautions

The trial was nonblinded, involved only 23 participants at one center, and compared groups of 12 and 11 patients. All neonates had favorable observed outcomes, leaving little power to detect uncommon harms or differences. The results apply to secondary or early latent syphilis, not other stages.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Sexually transmitted infections (PubMed). Single versus three doses of benzathine penicillin G for early syphilis in pregnancy: no added benefit in serological response or neonatal outcomes.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of clinical nursing (PubMed)Jul 16, 2026Systematic ReviewPractice applicable

A mixed-methods systematic review of 18 studies found that continuous bedside pressure mapping supported timelier repositioning and staff and patient awareness, but randomized trials did not show a significant overall preventive effect on pressure injuries.

Med-SurgAI summaryReview source

Systematic ReviewResearchWorkflowQuality ImprovementPractice applicableAI summary · original source linked below

This prospectively registered mixed-methods systematic review searched eight databases and included 18 studies of continuous bedside pressure mapping in adult hospital and long-term care settings. Observational cohorts suggested lower pressure-injury incidence in selected high-risk settings, but randomized trials found no significant overall preventive effect. An exploratory meta-analysis of interface pressure showed a borderline reduction with substantial heterogeneity that was not robust in sensitivity analysis. Process findings were more encouraging: the technology was associated with timelier repositioning, greater staff knowledge, and patient awareness and acceptability. The authors position pressure mapping as decision support alongside established prevention protocols, not as a stand-alone intervention.

Key takeaways

The review included 18 studies across adult hospital and long-term care settings.
Randomized trials did not show a significant overall pressure-injury prevention effect.
The exploratory interface-pressure result was borderline, heterogeneous, and not robust to sensitivity analysis.
Pressure mapping was associated with timelier repositioning and greater staff and patient awareness.

Why this matters on shift

Wound-care nurses and bedside teams often lead repositioning, skin surveillance, and pressure-injury prevention workflows. This review matters because it separates useful workflow feedback from the still-uncertain evidence that the technology prevents injuries.

Bedside takeaway

Bedside pressure mapping may improve repositioning workflows, but current randomized evidence does not show clear pressure-injury prevention.

Nursing implications

Use continuous pressure mapping, where approved, to inform repositioning and patient education while continuing established risk assessment, skin inspection, support-surface, and repositioning protocols. Evaluate workload, alert thresholds, and local outcomes rather than assuming that better process measures guarantee fewer injuries.

Limitations & cautions

The 18 studies used varied designs, settings, protocols, and outcomes. Observational findings may be confounded, randomized trials did not show a significant overall preventive effect, and the exploratory pressure meta-analysis had substantial heterogeneity and was not robust to sensitivity analysis. Economic evidence was also limited.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of clinical nursing (PubMed). The Effectiveness of Continuous Bedside Pressure Mapping for Pressure Injury Prevention: A Mixed-Methods Systematic Review.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Nurse-led telehealth lowered HbA1c, without clear BMI or fasting-glucose improvement

Three penicillin doses did not improve early-syphilis pregnancy outcomes versus one dose in a small trial

Bedside pressure mapping improved repositioning processes, but randomized trials did not show clear pressure-injury prevention